Beutel, Goodman & Co’s Pfizer PFE Stock Holding History

Beutel, Goodman & Co’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$26K	Hold	1,100	–	–	﹤0.01%	148
2026 Q1	$30K	Hold	1,100	–	–	﹤0.01%	143
2025 Q4	$27K	Hold	1,100	–	–	﹤0.01%	145
2025 Q3	$28K	Hold	1,100	–	–	﹤0.01%	143
2025 Q2	$26K	Sell	1,100 -16,725	-94%	-$390K	﹤0.01%	146
2025 Q1	$451K	Buy	+17,825	New	+$466K	﹤0.01%	117
2018 Q3	–	Sell	-506	Closed	-$13K	–	64
2018 Q2	$13K	Hold	506	–	–	﹤0.01%	62
2018 Q1	$13K	Sell	506 -1,634	-76%	-$56.2K	﹤0.01%	65
2017 Q4	$59K	Buy	+2,140	New	+$73K	﹤0.01%	67

Other funds holding PFE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Beutel, Goodman & Co's PFE Position: Q2 2026 in Review

Beutel, Goodman & Co held its Pfizer (PFE) position steady in Q2 2026 at 1,100 shares worth $26K. The position accounts for ﹤0.01% of the portfolio, ranked #148.

Beutel, Goodman & Co first reported a position in PFE in Q4 2017 and has held it in 9 quarters since. The position peaked at $451K in Q1 2025. 2,818 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

Beutel, Goodman & Co held 1,100 shares of Pfizer worth $26K as of Q2 2026.
Beutel, Goodman & Co left its Pfizer share count unchanged in Q2 2026.
Pfizer made up ﹤0.01% of Beutel, Goodman & Co's portfolio in Q2 2026, its #148 holding.
Beutel, Goodman & Co first reported a position in Pfizer in Q4 2017 and has held it in 9 quarters since.
Beutel, Goodman & Co's Pfizer position peaked at $451K in Q1 2025.
2,818 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Beutel, Goodman & Co's 13F filing for Q2 2026, filed 12 Aug 2026.